Dual-Terminal GnRH Immunogen for Potent Hormone Ablation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunization methods using GnRH or its mimetics face challenges in eliciting a potent immune response due to the small size and autologous nature of the decapeptide, leading to insufficient antibody production and variability in response among individuals, along with the use of reactogenic adjuvants and complex conjugation processes.
Innovation Solution
The simultaneous administration of GnRH or its mimetics bound to carrier molecules via both the carboxyl and amino terminal extremes in the same formulation, generating a synergistic immune response, allowing for faster and more potent ablation of sexual hormones and tumor reduction, using a combination of carboxyl and amino terminal variants with different carrier proteins or epitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GnRH or its mimetics are used as immunogen, then the immune response is insufficient due to small size and autologous nature, but using carrier molecules increases immunogenicity while adding complexity to the conjugation process
Solution Approach 1:
The patent divides the GnRH molecule into two separate variants: one conjugated at the amino terminal and another at the carboxyl terminal. This segmentation allows each variant to be optimized independently for immunogenicity while simplifying the overall conjugation strategy, as each variant uses a standard conjugation method at a specific terminal rather than requiring complex multi-site conjugation.
Solution Approach 2:
The patent combines both amino-terminal and carboxyl-terminal variants of GnRH in a single pharmaceutical composition. This merging of multiple immunogenic variants delivers enhanced overall immunogenicity through synergistic immune response, while each individual variant maintains a relatively simple conjugation structure.
2Reliability
If traditional adjuvants are used to enhance immune response, then antibody production increases but reactogenicity and side effects increase
Solution Approach 1:
The patent changes the key parameter of immunogenicity by using dual-terminal conjugation of GnRH variants, which inherently enhances immune recognition and antibody production. This parameter change allows the use of less reactogenic adjuvants, as the improved immunogenicity of the dual-variant composition compensates for the reduced potency of milder adjuvants.
3Ease of manufacture
If single variant of GnRH is used, then the conjugation process is simpler but the immune response shows variability among individuals
Solution Approach 1:
The patent segments the GnRH immunogen into two variants conjugated at different terminals. This segmentation targets different epitopic regions of the GnRH molecule, ensuring that individuals with varying immune responses to a single variant will still receive comprehensive immune coverage from the combined variants, thereby improving response consistency.
Solution Approach 2:
The pharmaceutical composition uses a composite of two GnRH variants with different conjugation patterns. This composite approach creates a more robust immunogen that overcomes individual variability in immune response, as the combined variants provide multiple pathways for immune recognition and antibody production.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A pharmaceutical composition using natural gonadotropin - releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.